A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 3.22 USD -0.92% Market Closed
Market Cap: 318.4m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+48%
Revenue
Forecast
+7%
Operating Income
Forecast
+4%
Net Income
Forecast
+5%

Wall Street
Price Targets

AQST Price Targets Summary
Aquestive Therapeutics Inc

Wall Street analysts forecast AQST stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AQST is 10.06 USD with a low forecast of 4.8 USD and a high forecast of 15.75 USD.

AQST Lowest Forecast
Wall Street Target
4.8 USD
49% Upside
AQST Average Forecast
Wall Street Target
10.06 USD
212% Upside
AQST Highest Forecast
Wall Street Target
15.75 USD
389% Upside
Lowest
Price Target
4.8 USD
49% Upside
Average
Price Target
10.06 USD
212% Upside
Highest
Price Target
15.75 USD
389% Upside
Aquestive Therapeutics Inc Competitors:
Price Targets
H
600566
Hubei Jumpcan Pharmaceutical Co Ltd
92% Upside
INVA
Innoviva Inc
12% Upside
ARVN
Arvinas Inc
423% Upside
SHILPAMED
Shilpa Medicare Ltd
80% Upside
H
600566
Hubei Jumpcan Pharmaceutical Co Ltd
92% Upside
INVA
Innoviva Inc
12% Upside
ARVN
Arvinas Inc
423% Upside
SHILPAMED
Shilpa Medicare Ltd
80% Upside
SUNPHARMA
Sun Pharmaceutical Industries Ltd
17% Upside
600750
Jiang Zhong Pharmaceutical Co Ltd
35% Upside
NATCOPHARM
Natco Pharma Ltd
35% Upside
H
13
HUTCHMED (China) Ltd
65% Upside

Revenue
Forecast

Revenue Estimate
Aquestive Therapeutics Inc

For the last 7 years the compound annual growth rate for Aquestive Therapeutics Inc's revenue is -2%. The projected CAGR for the next 3 years is 35%.

-2%
Past Growth
35%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Aquestive Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Aquestive Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-56%
Average Miss
What are analyst estimates?

See Also

Summary
AQST intrinsic value, competitors valuation, and company profile.
DCF Valuation
AQST stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AQST stock valuation using valuation multiples.
Wall Street Estimates
AQST price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AQST stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AQST's stock price target?
Price Target
10.06 USD

According to Wall Street analysts, the average 1-year price target for AQST is 10.06 USD with a low forecast of 4.8 USD and a high forecast of 15.75 USD.

What is Aquestive Therapeutics Inc's Revenue forecast?
Projected CAGR
35%

For the last 7 years the compound annual growth rate for Aquestive Therapeutics Inc's revenue is -2%. The projected CAGR for the next 3 years is 35%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 241,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.